The acute effect of fludrocortisone on basal and hCRH-stimulated hypothalamic-pituitary-adrenal (HPA) axis in humans

Pituitary

Volumn 16, Issue 3, 2013, Pages 378-385

  Karamouzis, Ioannis ^a   Berardelli, Rita ^a   Marinazzo, Elisa ^a   D'Angelo, Valentina ^a   Zinnà, Domenico ^a   Minetto, Marco Alessandro ^a   Zichi, Clizia ^a   Fussotto, Beatrice ^a   Giordano, Roberta ^b   Ghigo, Ezio ^a   Arvat, Emanuela ^a  

^a MOLINETTE HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

ACTH; Cortisol; Fludrocortisone; Glucocorticoid feedback; MR

Indexed keywords

ALDOSTERONE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; FLUDROCORTISONE; HYDROCORTISONE; PLACEBO;

ACTH SECRETING CELL; ADULT; ARTICLE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; HORMONAL REGULATION; HUMAN; HYDROCORTISONE RELEASE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; PRIORITY JOURNAL;

EID: 84881369520     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-012-0435-3     Document Type: Article

References (38)

1. Gaillard RC, Al-Damluji S (1987) Stress and the pituitary-adrenal axis. Baillieres Clin Endocrinol Metab 1(2):319-354
2. Orth DN (1992) Corticotropin-releasing hormone in humans. Endocr Rev 13:164-191
3. Jacobson L, Sapolsky R (1991) The role of the hippocampus in feedback regulation of the hypothalamic-pituitary-adrenocortical axis. Endocr Rev 12:118-134
4. De Kloet ER, Vreugdehil E, Oitzl MS, Joels M (1998) Brain corticosteroid receptor balance in health and disease. Endocr Rev 19(3):269-301
5. Arvat E, Maccagno B, Giordano R, Pellegrino M, Broglio F, Gianotti L, Maccario M, Camanni F, Ghigo E (2001) Mineralocorticoid receptor blockade by canrenoate increases both spontaneous and stimulated adrenal function in humans. J Clin Endocrinol Metab 86(7):3176-3181
6. Grottoli S, Giordano R, Maccagno B, Pellegrino M, Ghigo E, Arvat E (2002) The stimulatory effect of canrenoate, a mineralocorticoid antagonist, on the activity of the hypothalamus-pituitary-adrenal axis is abolished by alprazolam, a benzodiazepine, in humans. J Clin Endocrinol Metab 87(10):4616-4620
7. Funder JW (1997) Glucocorticoid and mineralcorticoid receptors: biology and clinical relevance. Annu Rev Med 48:231-240
8. Ribeiro RC, Kushner PJ, Baxter JD (1995) The nuclear hormone receptor gene superfamily. Annu Rev Med 46:443-453
9. Grossmann C, Scholz T, Rochel M, Bumke-Vogt C, Oelkers W, Pfeiffer AF, Diederich S, Bahr V (2004) Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties. Eur J Endocrinol 151(3):397-406
10. Reul JM, de Kloet ER (1985) Two receptor systems for corticosterone in rat brain: microdistribution and differential occupation. Endocrinology 117(6):2505-2511
11. Reul JM, Gesing A, Droste S, Stec IS, Weber A, Bachmann C, Bilang-Bleuel A, Holsboer F, Linthorst AC (2000) The brain mineralocorticoid receptor: greedy for ligand, mysterious in function. Eur J Pharmacol 405(1-3):235-249
12. Dallman MF, Levin N, Cascio CS, Akana SF, Jacobson L, Kuhn RW (1989) Pharmacological evidence that the inhibition of diurnal adrenocorticotropin secretion by corticosteroids is mediated via type I corticosterone-preferring receptors. Endocrinology 124(6):2844-2850
13. Spencer RL, Miller AH, Moday H, Stein M, McEwen BS (1993) Diurnal differences in basal and acute stress levels of type I and type II adrenal steroid receptor activation in neural and immune tissues. Endocrinology 133(5):1941-1950
14. Kalman BA, Spencer RL (2002) Rapid corticosteroid-dependent regulation of mineralocorticoid receptor protein expression in rat brain. Endocrinology 143(11):4184-4195
15. Otte C, Jahn H, Yassouridis A, Arlt J, Stober N, Maass P, Wiedemann K, Kellner M (2003) The mineralcorticoid receptor agonist, fludrocortisone, inhibits pituitary-adrenal activity in humans after pre-treatment with metyrapone. Life Sci 73(14):1835-1845
16. Otte C, Yassouridis A, Jahn H, Maass P, Stober N, Wiedemann K, Kellner M (2003) Mineralocorticoid receptor-mediated inhibition of the hypothalamic-pituitary-adrenal axis in aged humans. J Gerontol A Biol Sci Med Sci 58(10):900-905
17. Herman JP, Prewitt CM, Cullinan WE (1996) Neuronal circuit regulation of the hypothalamo-pituitary-adrenocortical stress axis. Crit Rev Neurobiol 10(3-4):371-394
18. Herman JP, Watson SJ, Spencer R (1999) Defense of adrenocorticosteroid receptor expression in rat hippocampus: effects of stress and strain. Endocrinology 140(9):3981-3991
19. Swanson LW, Sawchenko PE, Lind RW, Rho JH (1987) The CRH motoneuron: differential peptide regulation in neurons with possible synaptic, paracrine, and endocrine outputs. Ann NY Acad Sci 512:12-23
20. Swanson LW (1991) Biochemical switching in hypothalamic circuits mediating responses to stress. Prog Brain Res 87:181-200
21. Oitzl MS, Van Haarst AD, Sutanto W, De Kloet ER (1995) Corticosterone, brain mineralocorticoid receptor (MRs) and the activity of the hypothalamic-pituitary-adrenal (HPA) axis: the Lewis rat as an example of increased central MR capacity and a hyporesponsive HPA axis. Psychoneuroendocrinology 20(6):655-675
22. Ratka A, Sutanto W, Bloemers M, De Kloet ER (1989) On the role of brain mineralocorticoid (type I) and glucocorticoid (type II) receptors in neuroendocrine regulation. Neuroendocrinology 50(2):117-123
23. Deuschle M, Weber B, Colla M, Muller M, Kniest A, Heuser I (1998) Mineralocorticoid receptor also modulates basal activity of hypothalamus- pituitary-adrenocortical system in humans. Neuroendocrinology 68(5):355-360
24. Young EA, Lopez JF, Murphy-Weinberg V, Watson SJ, Akil H (1998) The role of mineralcorticoid receptors in hypothalamo-pituitary-adrenocortical axis regulation in humans. J Clin Endocrinol Metab 83(9):3339-3345
25. Born J, De Kloet ER, Wenz H, Kern W, Fehm HL (1991) Gluco- and antimineralocorticoid effects on human sleep: a role of central corticosteroid receptors. Am J Physiol 260:183-188
26. Wellhoener P, Born J, Fehm HL, Dodt C (2004) Elevated resting and exercise-induced cortisol levels after mineralocorticoid receptor blockade with canrenoate in healthy humans. J Clin Endocrinol Metab 89(10):5048-5052
27. Giordano R, Bo M, Pellegrino M, Vezzari M, Baldi M, Picu A, Balbo M, Bonelli L, Migliaretti G, Ghigo E, Arvat E (2005) Hypothalamus-pituitary-adrenal hyperactivity in human aging is partially refractory to stimulation by mineralcorticoid receptor blockade. J Clin Endocrinol Metab 90(10):5656-5662
28. Dodt C, Kern W, Fehm HL, Born J (1993) Antimineralocorticoid canrenoate enhances secretory activity of the hypothalamus-pituitary-adrenocortical (HPA) axis in humans. Neuroendocrinology 58(5):570-574
29. Funder JW, Carey RM, Fardella C, Gomez-Sanchez GE, Mantero F, Stowasser M, Young FW Jr, Montori VM (2008) Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93:3266-3281
30. Berardelli R, Karamouzis I, Marinazzo E, Prats E, Picu A, Giordano R, Ghigo E, Arvat E (2010) Effect of acute and prolonged mineralocorticoid receptor blockade on spontaneous and stimulated hypothalamic-pituitary-adrenal axis in humans. Eur J Endocrinol 162(6):1067-1074
31. Giordano R, Pellegrino M, Picu A, Bonelli L, Oleandri SE, Pellissetto C, Limone P, Migliaretti G, Maccario M, Ghigo E, Arvat E (2007) Primary hyperaldosteronism is associated with derangement in the regulation of the hypothalamus-pituitary-adrenal axis in humans. J Endocrinol Invest 30(7):558-563
32. Heuser I, Deuschle M, Weber B, Stalla GK, Holsboer F (2000) Increased activity of the hypothalamus-pituitary-adrenal system after treatment with the mineralocorticoid receptor antagonist spironolactone. Psychoneuroendocrinology 25(5):513-518
33. Vogt W, Fischer I, Ebenroth S, Appel S, Knedel M, Lücker PW, Rennekamp H (1971) Pharmacokinetics of 9-fluorhydrocortisone. Arzneimittelforschung 21(8):1133-1143
34. Buckley TM, Mullen BC, Schatzberg AF (2007) The acute effects of a mineralocorticoid receptor (MR) agonist on nocturnal hypothalamic-adrenal- pituitary (HPA) axis activity in healthy controls. Psychoneuroendocrinology 32(8-10):859-864
35. Arvat E, Maccagno B, Ramunni J, Di Vito L, Giordano R, Gianotti L, Broglio F, Camanni F, Ghigo E (1999) The inhibitory effect of alprazolam, a benzodiazepine, overrides the stimulatory effect of metyrapone-induced lack of negative cortisol feedback on corticotroph secretion in humans. J Clin Endocrinol Metab 84:2611-2615
36. Grottoli S, Maccagno B, Ramunni J, Di Vito L, Giordano R, Gianotti L, Destefanis S, Camanni F, Ghigo E, Arvat E (2002) Alprazolam, a benzodiazepine, does not modify the ACTH and cortisol response to hCRH and AVP, but blunts the cortisol response to ACTH in humans. J Endocrinol Invest 25:420-425
37. Hügin-Flores ME, Steimer T, Aubert ML, Schulz P (2004) Mineralo- and glucocorticoid receptor mrnas are differently regulated by corticosterone in the rat hippocampus and anterior pituitary. Neuroendocrinology 79(4):174-184
38. Roubos EW, Kuribara M, Kuipers-Kwant FJ, Coenen TA, Meijer KH, Cruijsen PM, Denver RJ (2009) Dynamics of glucocorticoid and mineralocorticoid receptors in the Xenopus laevis pituitary pars intermedia. Ann NY Acad Sci 1163:292-295